MindWalk Holdings Corp. (Nasdaq: HYFT), a Bio-Native AI company, has announced a breakthrough discovery validating its platform’s precision in targeting pathogenic forms of the TDP-43 protein, a key driver in neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain subtypes of Alzheimer’s disease. The company identified and validated monoclonal antibodies and intrabodies that selectively bind to misfolded, disease-causing TDP-43 while sparing its healthy, functional form—a critical advancement in the field of neurodegenerative drug development. This achievement underscores MindWalk’s ability to distinguish between toxic protein conformations and their native counterparts with structural precision, a longstanding challenge in developing targeted therapies. By defining the disease-specific structural state of TDP-43 and validating it through rigorous wet-lab experiments, the company has established a clear link between molecular structure and disease function. This integrated approach transforms biological insight into validated, traceable therapeutic assets. “We are proving that our platform can identify disease-defining protein states and convert that knowledge into highly selective, biologically validated candidates,” said Dr. Jennifer Bath, President and CEO of MindWalk. “This discovery is not just about one target—it’s a validation of our entire platform strategy, demonstrating our ability to deliver precision, speed, and scientific rigor in complex neurodegenerative programs.” The research, published as a preprint on bioRxiv (DOI: 10.1101/2025.06.10.658846), titled Rational Generation of Monoclonal Antibodies and Intrabodies Selective for Pathogenic TDP-43, provides external validation of MindWalk’s technology in a client-driven context. It reinforces the company’s role as a trusted partner for pharmaceutical and biotech organizations advancing high-risk, high-reward neurodegenerative programs. MindWalk’s proprietary HYFT® technology and LensAI™ platform integrate sequence, structure, function, and scientific literature into a unified computational framework. The system enables rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics—accelerating the path from insight to validated candidate. The platform’s strength lies in closing the loop between computational prediction and experimental validation in a fully integrated wet-lab environment. The company emphasizes that while the findings are promising, they are based on preclinical data from a preprint that has not yet undergone peer review. As such, the results are subject to further scientific scrutiny, additional validation, and the inherent risks of drug development, including reproducibility, selectivity, safety, pharmacology, and manufacturability. The translation of these findings into clinical applications remains uncertain and will depend on future research, regulatory approval, and collaboration. MindWalk continues to advance its platform capabilities and strategic partnerships, aiming to bring precision therapeutics to patients suffering from currently untreatable neurodegenerative conditions. The company remains committed to innovation, execution, and delivering on its vision of transforming drug discovery through AI-powered, biologically grounded science. For more information, visit the full study on bioRxiv or contact MindWalk’s investor relations team at [email protected].